Provided by Tiger Fintech (Singapore) Pte. Ltd.

Minerva Neurosciences

1.54
-0.0800-4.94%
Post-market: 1.540.00000.00%16:08 EDT
Volume:11.22K
Turnover:18.02K
Market Cap:10.77M
PE:8.11
High:1.66
Open:1.62
Low:1.54
Close:1.62
Loading ...

Company Profile

Company Name:
Minerva Neurosciences
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
8
Office Location:
1500 District Avenue,Burlington,Massachusetts,United States
Zip Code:
01803
Fax:
- -
Introduction:
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Remy Luthringer
Chief Executive Officer and Executive Chairman of the Board
David Kupfer
Director
Fouzia Laghrissi Thode
Director
Hans Peter Hasler
Director
Jan van Heek
Director

Shareholders

Name
Position
Remy Luthringer
Chief Executive Officer and Executive Chairman of the Board
Frederick Ahlholm
SVP, Chief Financial Officer and Secretary
Geoffrey Race
President